Macrophage Pharma Limited, a Windsor, England, UK-based immuno-oncology research and development company focused on macrophage modulation in the tumour microenvironment (TME), raised additional funding from Merck Ventures to complete the Series A Financing announced in January 2017.
Merck Ventures joined the existing investor syndicate of CRT Pioneer Fund (CPF), Novo Holdings A/S and Aglaia Biomedical Ventures BV with an equal size of investment. Senior Investment Director Hakan Goker from Merck Ventures joins Macrophage Pharma’s Board of Directors.
The financing will enable Macrophage Pharma to complete the first clinical study of its lead development candidate, a macrophage targeted p38MAP kinase inhibitor, as well as advancing two additional discovery candidates into preclinical development. The company is also planning to use the additional capital by adding a fourth macrophage-targeted project into its pipeline.
Led by Joanne Bedwell-Garner, Development Director, Steven Powell, Executive Director, David Moffat, Director of Chemistry, Martin Perry, Director of Biology, Macrophage Pharma is advancing the ESM™ technology platform designed to deliver small molecule drugs to macrophages in a highly selective manner, activating the body’s natural immune system to fight cancer.
The ESM™ technology platform has the ability to provide next-generation immunotherapies for a number of different cancers and larger patient populations.
The company’s lead p38MAPi program is focused on a novel macrophage-targeting p38 MAPK inhibitor. Clinical trials are scheduled to start in 2018. Macrophage Pharma is also developing additional programmes against novel targets centred on a number of proprietary, candidate compounds.